TECELRA
Adaptimmune Therapeutics, a leader in cell therapy, revolutionized cancer treatment with afamitresgene autoleucel, the first FDA-approved engineered cell therapy targeting a solid tumor. This groundbreaking therapy utilizes T-cell receptors (TCRs) to recognize and attack cancer cells. To effectively communicate this innovative approach, Brandsymbol collaborated with Adaptimmune to develop a naming strategy that emphasized the TCR component and distinguished TECELRA® from established CAR T therapies.
Brandsymbol worked with the Adaptimmune team to create both the generic name, afamitresgene autoleucel, and the brand name, TECELRA®. TECELRA®, reflects this focus on TCR technology. “TE” references the critical role of T-cell engineering, leveraging the novelty of this first-to-market TCR therapy. This strategic approach ensures clear differentiation within the oncology space, where CAR T-cell therapies are more prevalent.
Through this collaborative effort, Brandsymbol and Adaptimmune achieved a naming outcome that not only met regulatory requirements but also effectively conveyed the product’s revolutionary nature. The successful approval of both names paved the way for TECELRA®’s commercial launch, solidifying Adaptimmune’s position as a leader in cell therapy.
